Study Shows Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test Improves Identification Of High Risk Disease In Tumors Of Intermediate T2/T3 Thickness

CHICAGO--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced updated study results with its noninvasive gene expression profile (GEP) test, demonstrating that the assay was able to accurately identify high risk disease in patients with tumors of intermediate thickness (T2/T3), independent of sentinel lymph node biopsy (SLNB) status and ulceration. The data are being presented today at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) during the Melanoma/Skin Cancers Poster Session by David H. Lawson, M.D., Professor of Hematology and Medical Oncology, Winship Cancer Institute, Emory University.

Help employers find you! Check out all the jobs and post your resume.

Back to news